Cargando…
Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction
Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is impeded by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially address...
Autores principales: | Tonry, Claire, Russell-Hallinan, Adam, McCune, Claire, Collier, Patrick, Harbinson, Mark, Dixon, Lana, Watson, Chris J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153425/ https://www.ncbi.nlm.nih.gov/pubmed/35640873 http://dx.doi.org/10.1093/cvr/cvac087 |
Ejemplares similares
-
Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis
por: McDonald, Kenneth, et al.
Publicado: (2020) -
The Essentials of Cardiac Computerized Tomography
por: McKavanagh, Peter, et al.
Publicado: (2015) -
Risk and Management of Patients with Cancer and Heart Disease
por: Hill, Loreena, et al.
Publicado: (2023) -
The impact of cardiac magnetic resonance viability assessment on the management of patients with ischaemic heart disease and left ventricular dysfunction
por: Cole, Ben, et al.
Publicado: (2015) -
Postgraduate Quiz
por: McCune, Claire, et al.
Publicado: (2015)